Dopamine News and Research

Latest Dopamine News and Research

Unhealthy coping behaviors lead to higher rates of physical health problems, earlier mortality

When people are under chronic stress, they tend to smoke, drink, use drugs and overeat to help cope with stress. These behaviors trigger a biological cascade that helps prevent depression, but they also contribute to a host of physical problems that eventually contribute to early death.

19 May 2010

New research shows link between mental health and creativity

New research shows a possible explanation for the link between mental health and creativity. By studying receptors in the brain, researchers at Karolinska Institutet have managed to show that the dopamine system in healthy, highly creative people is similar in some respects to that seen in people with schizophrenia.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

Experts address fundamental questions related to renal failure in ICU

Despite the fact that recent medical advances have allowed healthcare professionals to stabilize patients who would have otherwise died, many stabilized patients later develop organ system failure. In fact, acute renal failure is one of the biggest threats to critically ill patients: forty percent of patients with this condition die.

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

Researchers discover molecular mechanism behind smoking cessation effect

The tobacco addiction epidemic is a major public health problem worldwide. Professor Zhao Baolu and his group from the State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Chinese Academy of Sciences set out to tackle this problem. After 20 years of innovative research, they have developed a novel tea filter to treat cigarette addiction and have discovered the molecular mechanism behind the smoking cessation effect.

12 May 2010

Study highlights benefits of using endometrial stem cells to restore functioning of brain cells

Stem cells derived from the endometrium (uterine lining) and transplanted into the brains of laboratory mice with Parkinson's disease appear to restore functioning of brain cells damaged by the disease, according to a new study by Yale School of Medicine researchers.

7 May 2010

Mouse study may lead to new therapies for Parkinson's disease

Endometrial stem cells injected into the brains of mice with a laboratory-induced form of Parkinson's disease appeared to take over the functioning of brain cells eradicated by the disease.

7 May 2010

Research makes progress in ending guesswork involved in prescribing effective ADHD medications

Children with ADHD who carry a specific type of dopamine receptor gene respond better to the drug methylphenidate than those without the genotype, according to new research from Cincinnati Children's Hospital Medical Center.

4 May 2010

UGA, Emory researchers awarded $1.9M grant to study role of regular exercise in attenuating drug abuse

A team of researchers at the University of Georgia and Emory University will receive $1.9 million over the next five years from the National Institutes of Health to study the neurobiological mechanisms for how regular aerobic exercise may prevent drug abuse relapse.

30 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Research finding sheds more light on the workings of lateral PFC

Whether it's for money, marbles or chalk, the brains of reward-driven people keep their game faces on, helping them win at every step of the way. Surprisingly, they win most often when there is no reward.

28 Apr 2010

New imaging protocol to visualize activity of brain's reward circuitry in individuals addicted to drugs

Researchers at the U.S. Department of Energy's Brookhaven National Laboratory have developed an imaging protocol that allows them to visualize the activity of the brain's reward circuitry in both normal individuals and those addicted to drugs. The technique could lead to better insight into why people take recreational drugs as well as help determine which treatment strategies might be most effective.

27 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

Medication and behaviour therapy help children with Attention Deficit Hyperactivity Disorder

Medication and behavioural interventions help children with Attention Deficit Hyperactivity Disorder (ADHD) better maintain attention and self control by normalising activity in the same brain systems, according to researchers at The University of Nottingham.

15 Apr 2010

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.

13 Apr 2010

Dopamine News and Research

Latest Dopamine News and Research

Unhealthy coping behaviors lead to higher rates of physical health problems, earlier mortality

New research shows link between mental health and creativity

152 research and training grants awarded to researchers at 93 institutions nationwide

Experts address fundamental questions related to renal failure in ICU

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Researchers discover molecular mechanism behind smoking cessation effect

Study highlights benefits of using endometrial stem cells to restore functioning of brain cells

Mouse study may lead to new therapies for Parkinson's disease

Research makes progress in ending guesswork involved in prescribing effective ADHD medications

UGA, Emory researchers awarded $1.9M grant to study role of regular exercise in attenuating drug abuse

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Research finding sheds more light on the workings of lateral PFC

New imaging protocol to visualize activity of brain's reward circuitry in individuals addicted to drugs

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Medication and behaviour therapy help children with Attention Deficit Hyperactivity Disorder

Patients with RLS using rotigotine achieve sustained improvements

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Dopamine News and Research

Latest Dopamine News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in